Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans
University Hospital, Gentofte, Copenhagen
18 participants
Apr 1, 2026
INTERVENTIONAL
Summary
The two pancreatic hormones amylin and pancreatic polypeptide (PP) has been linked to satiety and energy metabolism. The goal of this this study is to determine the separate and combined effects of the two hormones on food intake and other exploratory endpoints related to metabolism in healthy humans. The aim of this study is to investigate the interaction between the hormones and obtain insight into the physiology of the hormones. The healthy participants will undergo 4 study days in a randomised order receiving the following infusions for 5 hours: A) Amylin + PP B) Amylin + Placebo C) Placebo + PP D) Placebo + Placebo Throughout the day blood samples will be collected and gallbladder motility will be evaluated. Further, indirect calorimetry and heart rate/blood pressure measurement will be performed.
Eligibility
Inclusion Criteria5
- Male
- Age between 18 and 65 years at the time of inclusion
- Body mass index 18-27 kg/m2
- Fat percentage < 20%
- Informed oral and written consent
Exclusion Criteria9
- Anaemia (haemoglobin below normal range)
- History of hepatobiliary and/or gastrointestinal disorder(s)
- Kidney disease
- Previous gastric or intestinal resection, cholecystectomy and/or any major intra- abdominal surgery (including bariatric surgery)
- Previous pancreatic disease and/or neoplasia
- Regular tobacco smoking and/or use of other nicotine products
- Glycated haemoglobin (HbA1c) ≥48 and/or type 1 diabetes or type 2 diabetes requiring medical treatment
- Initiation of special diets, lifestyle changes and/or weight loss >5% of total body weight within three months prior to or during study period
- Any physical or psychological condition or ongoing medication the investigator group suspects would interfere with trial participation
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
This a one of the pancreatic hormones investigated in this study. Pramlintide is used a surrogate for amylin due to the fibrillating properties of amylin
This a one of the pancreatic hormones investigated in this study.
This the placebo
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07506369